New pharmacological treatments used in psoriasis: integrative review
DOI:
https://doi.org/10.33448/rsd-v10i15.22717Keywords:
Psoriasis; Treatment; Pharmacological therapy.; Pharmacological therapyAbstract
Psoriasis is a chronic, non-communicable disease that can cause acute pain and disfigurement to the patient, with pharmacological therapy as a satisfactory alternative with the use of retinoids, immunosuppressants and immunobiologicals that provide a great impact on the quality of life of patients, who constantly seek better forms of therapies that demonstrate effective results in controlling the disease. Thus, the article sought to describe the new treatment approaches for psoriasis available in the pharmaceutical market. The research was characterized by being an integrative literature review with data collection in the Lilacs, Medline and Scielo databases, according to the inclusion and exclusion criteria, from a total of 197 articles, 16 were selected to compose the analysis. As a result, there was an application of systemic therapy, with a combination of phototherapy with methotrexate, acitretin, cyclosporine, and biological drugs such as ixequizumab, guselcumab, secukinumab, adalimumab, infliximab, in addition to those for their children. With the study, it is possible to identify which drugs can act in the treatment of psoriasis, such as naltrexone, rottlerin, in addition to the use of an aerosol of calcipotriol and betamethasone dipropionate, and therapy techniques with microinfusion and iontophoresis for the treatment. The possibilities for treating the disease are mainly in the use of drugs, for patients, the main barriers are accessibility, medication usage, and adverse effects that contribute to advances in the remission of the disease.
References
Álvares J., Alves, M. C. G. P., Escuder, M. M. L., Almeida, A. M., Izidoro, J. B., Júnior, A. A., Costa, K. S., Costa, E. A., Guibu, I. A., Soeiro, O. M., Leite, S. N., Karnikowski, M. G. O., & Acurcio, F. de A. (2017). Pesquisa nacional sobre acesso, utilização e promoção do uso racional de medicamentos: métodos. Revista de Saúde Pública, 51 (supl.2), 4s. https://doi.org/10.11606/S1518-8787.2017051007027
Amarante, M. S. L. D., Sena, N. V., Vieira, A. F., Pontes, L. M., Santos, P. R., & Souza, M. L. P. (2021). Perfil epidemiológico dos pacientes com diagnóstico de psoríase atendidos na BWS, São Paulo-SP. BWS Journal, 3 (2), e20080094: 1-6. https://bwsjournal.emnuvens.com.br/bwsj/article/view/94/75
Antonio, J. R., Rossi, N. C. P., Azevedo, F. L., De Oliveira, G. B., & Antonio, C. R. (2015). Infliximabe no tratamento da psoríase associada a doença de Crohn: elato de caso. Med Cutan Iber Lat Am., 43 (3), 199-201. https://www.medigraphic.com/pdfs/cutanea/mc-2015/mc153f.pdf
Associação da Indústria Farmacêutica de Pesquisa. (2019). Novas terapias, novos métodos de pagamento e a convergência tecnológica (1a ed.). Company Graf Produções Gráficas e Editora Ltda.
Bernardes, M. T. C. P. (2021). Desenvolvimento de cristais líquidos e hidrogéis para administração cutânea de metotrexato para tratamento de psoríase [Tese de Doutorado, Universidade Federal de Alfenas], BDTD Unifal. https://bdtd.unifal-mg.edu.br:8443/handle/tede/1789
Bidoia, S. F. D. P., Roncada, E. V. M., Schaefer, L. V., De Abreu, M. A. M. M., Shimizu, G. K. M., & Gasparini, K. T. (2018). Psoríase pustulosa palmoplantar como efeito paradoxal do uso de adalimumabe: relato de caso. Revista diagnóstico e tratamento, 23 (2), 45-49. https://docs.bvsalud.org/biblioref/2018/06/904891/rdt_v23n2_45-49.pdf
Blauvelt, A, Papp, K, Gottlieb, A, Jarell, A, Reich, K, Maari, C, Gordon, K. B, Ferris, L. K, Langley, R. G, Tada, Y., Lima, R. G, Elmaraghy, H, Gallo, G, Renda, L, Park, S. Y, Burge, R, & Bagel, J. (2020). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol, 182 (6), 1348-1358. http://doi.org/10.1111/bjd.18851
Botelho, S. F., Martins, M. A. P., & Reis, A. M. M. (2018) Análise de medicamentos novos registrados no Brasil na perspectiva do Sistema Único de Saúde e da carga de doença. Ciência & Saúde Coletiva, 23 (1), 215-228. https://doi.org/10.1590/1413-81232018231.21672015
Canha, R. I. C. (2019). Intervenção farmacêutica em doenças autoimunes: psoríase e lúpus [Dissertação de Mestrado, Universidade do Algarve], Sapientia. https://sapientia.ualg.pt/handle/10400.1/13655
Carvalho, C, Gonçalves, L. V. A., & Rodrigues, T. R. A. (2018). Tratamento alternativo para psoríase: relato de caso. Revista Ciência e Saúde On-line, 3(3). https://revistaeletronicafunvic.org/index.php/c14ffd10/article/view/111
Castilho, A. C. S., Lopes, C. O. P., & Salles, B. C. C. (2021). Fisiopatologia da psoríase e seus aspectos imunológicos: uma revisão sistemática. Research, Society and Development, 10 (11), e256101119346-e256101119346. https://doi.org/10.33448/rsd-v10i11.19346
Chandrappa, N. K. A., Ravikumar, B. C., & Rangegowda, S. M. (2020). Iontophoretic delivery of methotrexate in the treatment of palmar psoriasis: a randomised controlled study. Australas J Dermatol, 61(2), 140-146. http://doi.org/10.1111/ajd.13228
Ercole, F. F., Melo, L. S., & Alcoforado, C. L. G. C. (2014). Revisão integrativa versus revisão sistemática. Revista Mineira de Enfermagem, 18 (1), n.1, 12-14. http://doi.org/10.5935/1415-2762.2014000
Fioratti, C, Mendoza, A. V, Rachid, M. L, Rosim, R, & Junqueira, M. (2018). Analise de custo por resposta de adalimumabe, etanercepte, guselcumabe, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe para tratamento de psoríase em placas moderada a grave sob a perspectiva do Sistema de Saúde Suplementar brasileiro. J. bras. econ. saúde (Impr.), 10 (3), 226-231. http://doi.org/ 10.21115/JBES.v10.n3.p226-31
Guenther, L, Bleakman, A. P, Weisman, J, Poulin, Y, Spelman, L, Burge, R, Erickson, J, Todd, K, Bertram, C. C, & Ryan, C. (2020). Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol, 100 (1), adv00006. http://doi.org/10.2340/00015555-3353
Ingram, M. A., Jones, M. B., Stonehouse, W., Jarrett, P., Scragg, R., & Mugridge, O. (2018). Oral vitamin D3 supplementation for chronic plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Dermatolog Treat, 29 (7), 648-657. http://doi.org/10.1080/09546634.2018
Khan, S, Ghafoor, R, & Kaleem, S. (2020). Efficacy of Low Dose Naltrexone in Psoriasis. J Coll Physicians Surg Pak, 30 (6), 579-583. http://doi.org/10.29271/jcpsp.2020.06.579
Lemos, T. P. (2017). Avaliação das vantagens e desvantagens no uso da isotretinoína no tratamento da psoríase no Brasil [Monografia, Centro Universitário São Lucas], AD São Lucas. http://repositorio.saolucas.edu.br:8080/xmlui/handle/123456789/2958?show=full
Lima, E. C., Boza, J. C., Palominos, P. E., Xavier, R. M., & Cestari, T. F. Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil. An Bras Dermatol, 96, 376–9. https://doi.org/10.1016/j.abd.2020.08.011
Min, M., Yan, B. X., Wang, P., Landeck, L., Chen, J. Q., Li, W., Cai, S. Q., Zheng, M., & Xiao-Yong, H. (2017). Rottlerin as a therapeutic approach in psoriasis: Evidence from in vitro and in vivo studies. PLoS ONE, 12 (12), e0190051. https://doi.org/10.1371/journal.pone.0190051
Ministério da Saúde. (2021). Protocolo Clínico e Diretrizes Terapêuticas da Psoríase. Brasília, DF: Ministério da Saúde.
Mota, C. C. F. (2019). Resposta terapêutica e tempo de sobrevida dos imunobiológicos em pacientes com psoríase moderada a grave [Dissertação de Mestrado, Universidade de São Paulo], BD USP. https://doi.org/10.11606/D.5.2019.tde-11122019-102844
Okita, A. L., Arbache, S., Roth, D. M. P., de Souza, L. G., Colferai, M. M. T., & Steiner, D. (2018). Tratamento de psoríase vulgar pela microinfusão de medicamentos na pele (MMP®) usando ciclosporina e metotrexato. Surgical & Cosmetic Dermatology, 10 (1), 80-84. http://doi.org/10.5935/scd1984-8773.20181011098
Pontes, C. E. C. (2017). Pharmaceutical patents and the national pharmaceutical industry: a study of the deposits made in Brazil. Revista Produção e Desenvolvimento, 3 (2), 38-51. https://doi.org/10.32358/rpd.2017.v3.213
Rezende, H. D., Milagre, A. C. X., Almeida, A. P. M., & Guimarães, L. C. B. (2017). Psoríase artropática eritrodérmica: rápida remissão com secuquinumabe. Revista Med Minas Gerais, 27, e-1885. http://doi.org/10.5935/2238-3182.20170073
Rocha, I. P., Bastos, N. L D. V. M., Santos, T. A., Lima, J. D., & Dos Santos, M. S. (2021). imunopatogênese da psoríase e principais fatores genéticos envolvidos. Revista Multidisciplinar Em Saúde, 2(2), 66. https://doi.org/10.51161/rems/1018
Sociedade Brasileira de Dermatologia. (2020). Consenso brasileiro de psoríase 2020: algoritmo de tratamento da Sociedade Brasileira de Dermatologia (3a ed.). SBD.
Souza, J. M., de Godoy, N. A., Pollo, C. F., Miot, H. A., & Meneguin, S. (2021). Percepção de dermatologistas sobre a influência da psoríase na qualidade de vida dos pacientes. Enfermería: Cuidados Humanizados, 10 (1), 18-29. https://doi.org/10.22235/ech.v10i1.2066
Velasco, M., Fernández, M. G., Martín, M. R., Regaña, S. S., & Barrio, D. P. (2019). Satisfacción del paciente y el médico con la espuma en aerosol de calcipotriol y dipropionato de betametasona para el tratamiento de la psoriasis vulgar en el cuerpo. Actas Dermo-Sifiliográficas, 110 (9), 752-758. https://doi.org/10.1016/j.ad.2019.03.013
Warren, R. B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T, Geng, Z, & Paul, C. (2021). Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol, 184 (1), 50-59. http://doi.org/10.1111/bjd.19341
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Denise Melgueiro Rocha; Omero Martins Rodrigues Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
